Trevena Inc.

An unsuccessful clinical trial is not automatically cause for rescinding a drug or biologic’s breakthrough therapy designation, the US Food and Drug Administration said in a new draft guidance. Rather

Rising Leaders Home Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive $100m series B round. CEO Ros Deegan, one of In Vivo ’s 2022 rising le

Initial public offerings in the US are in a slump, with just nine biopharmaceutical company IPOs during the first quarter, raising a total of $807m. The Q1 tally is a fraction of the offerings and the

Recent days have made clear some upcoming milestones in two of the most vexing therapeutic areas: COVID-19 and Alzheimer’s disease. The race to develop a treatment for COVID-19 saw the first submissio